Drug news
NICE rejects Afinitor (everolimus) from the Cancer Drugs Fund as a treatment for breast cancer.-Novartis
The National Institute for Health and Care Excellence (NICE) has published guidelines rejecting from the Cancer Drugs Fund, Afinitor (everolimus) from Novartis, plus exemestane, as a cost effective treatment for postmenopausal women with advanced breast cancer that is HER 2 negative and hormone receptor positive and that has worsened or recurred. New overall survival data suggest the combination is less clinically effective originally thought.